Advertisement

Topics

FDA approves ReNeuron’s cryopreserved formulation of retinal stem cell therapy candidate

08:25 EDT 20 Jun 2017 | Healio

The FDA has approved the cryopreserved formulation of ReNeuron Group’s human retinal progenitor cell therapeutic candidate, according to a company press release. Patients with retinitis pigmentosa are now being treated with the formulation in a phase 1/2 clinical trial. The formulation allows cells to be frozen for shipping and storage and thawed for clinical use, increasing shelf life and lowering cost, the release said.

Original Article: FDA approves ReNeuron’s cryopreserved formulation of retinal stem cell therapy candidate

NEXT ARTICLE

More From BioPortfolio on "FDA approves ReNeuron’s cryopreserved formulation of retinal stem cell therapy candidate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...